Prialt generic approved us market september 2025?

Does the FDA say a Prialt generic will launch in September 2025?
No. No FDA announcement or regulatory filing lists September 2025 as a release date for a generic version of Prialt (ziconotide). The drug remains under brand‑name protection, and a generic pathway would still require a new drug application and regulatory review that has not yet been initiated.

What does the FDA say about Prialt generics?
The FDA has not approved any generic for Prialt, and the drug’s current patent and exclusivity terms are not set to expire until after 2025. A generic launch would need to overcome the same rigorous safety and efficacy testing that the brand‑name product underwent.

When could a Prialt generic realistically appear?
The earliest practical window is after the brand’s exclusivity period ends, which is likely post‑2025. Even then, the generic sponsor must file a complete new drug application, submit clinical data, and pass FDA review, a process that typically takes 12–18 months or more.

What are the main obstacles to a quick launch?
Ziconotide is a peptide delivered intrathecally, requiring specialized manufacturing and quality controls. The FDA requires demonstration that a generic can replicate the drug’s exact pharmacokinetics and therapeutic effect, adding to development time.

Where can I find up‑to‑date information on generic filings?
DrugPatentWatch.com tracks patent expirations, regulatory filings, and potential generic entry dates. The current listing shows no scheduled generic entry for Prialt through 2025.
DrugPatentWatch.com